Pregled bibliografske jedinice broj: 1134890
VWF-FVIII concentrates in the treatment of inherited von Willebrand disease: A single-centre retrospective study
VWF-FVIII concentrates in the treatment of inherited von Willebrand disease: A single-centre retrospective study // Haemophilia (Oxford), 25 (2019), 4; e300-e303 doi:10.1111/hae.13779. (međunarodna recenzija, pismo, znanstveni)
CROSBI ID: 1134890 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
VWF-FVIII concentrates in the treatment of
inherited von Willebrand disease: A single-centre
retrospective study
Autori
Boban, Ana ; Lambert, Catherine Marie ; Hermans, Cedric
Izvornik
Haemophilia (Oxford) (1351-8216) 25
(2019), 4;
E300-e303
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo, znanstveni
Ključne riječi
von Willebrand disease ; VWF concentrate ; DDAVP ; treatment ; prophylaxis
Sažetak
Only a minority of VWD patients needed treatment with VWF concentrate, namely 18% of all VWD patients followed at our center during the 15-year study period. Besides Type 3 VWD, VWF concentrates were commonly used in patients with severe disease, regardless of VWD type. In case of mild and moderate disease, the treatment modality mostly depended on the indication for hemostatic therapy. Our study has confirmed that the absolute indications for using VWF concentrates in VWD patients are prophylaxis, major surgeries, and nonresponsiveness/ contraindications to DDAVP.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Ana Boban
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
